Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?

ÖZTÜRK, ERKAN; KILBAŞ, Zafer; YILDIZ, Ramazan

Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?

Zafer KILBAŞ, (GATA Genel Cerrahi Anabilim Dalı, Ankara, Türkiye)

Ramazan YILDIZ, (GATA Genel Cerrahi Anabilim Dalı, Ankara, Türkiye)

Erkan ÖZTÜRK (GATA Genel Cerrahi Anabilim Dalı, Ankara, Türkiye)

TSK Koruyucu Hekimlik Bülteni

18 7

Yıl: 2012 Cilt: 11 Sayı: 2 Sayfa Aralığı: 225 - 230 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?

Öz:

Meme kanseri kadınlarda en sık görülen kanserdir ve kadınlarda kansere bağlı ölümlerin ikinci en sık nedenidir. Batı ülkelerinde meme kanseri insidansı gelişmekte olan ülkelere kıyasla daha yüksek olmasına rağmen, kansere bağlı mortalitenin daha düşük olması yaygın ve etkili tarama programlarının uygulanması ile kanserin erken evrede yakalanıp tedavi edilmesine bağlanmaktadır. Mamografi tarama amacıyla uzun zamandır kullanımda olmasına rağmen, taramaya ne zaman başlanması gerektiği, ne sıklıkla uygulanacağı ve ne zaman sonlandırılacağı ile ilgili halen kesin uzlaşılar yoktur. Ülkeler kendi tarama programlarını oluştururken hastanın risk durumu, meme kanseri insidansı, sosyal ve ekonomik faktörler, mamografi ve sağlık ekibinin yeterliliği gibi birçok unsuru gözönünde bulundurmalıdır. Günümüzde meme kanserine bağlı mortaliteyi azaltmanın en etkin yolu erken tanı ve tedavidir. Etkili tarama programları ve meme kanseri farkındalığını arttırıcı organizasyonlar sayesinde meme kanserini erken evrede saptamak ve kansere bağlı mortaliteyi azaltmak mümkündür.

Anahtar Kelime:

Konular: Tamamlayıcı ve Entegre Tıp Onkoloji

How should the screening programs be planned for the early diagnosis of breast cancer

Öz:

Breast cancer is the most common cancer of women, and it ranks as the second leading cause of cancer death in women. Although breast cancer incidence in western countries is higher than developping countries, very favorable survival rates in the developed countries have been attributed to early detection by screening. Despite screening mammography have been used for a long time, there is not a strong consensus related to when to start?, how frequently to screen?, and when to finish screening. Many factors including the risk stratification of patient, incidence of breast cancer, social and economic status, the availability of mammography and medical team should be considered when creating national screening programs. Today, the most effective way to reduce breast cancer mortality is early diagnosis and treatment. By the help of effective screening programmes and organizations related to breast cancer awareness, downstaging of breast cancer and reduction in mortality rate in community could be possible.

Anahtar Kelime:

Konular: Tamamlayıcı ve Entegre Tıp Onkoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212.
2. Özmen V, Fidaner V, Aksaz Ğ, Bayol W, Dede İ, Göker E ve ark. Türkiye’de Meme Kanseri Erken Tanı ve Tarama Programlarının Hazırlanması. Meme Sağlığı Dergisi. 2009; 5(3): 125-134
3. Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007; 99(23): 1782-92.
4. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81(24): 1879- 86.
5. www.seer.cancer.gov/csr/1975_2000/ [Erişim Tarihi: 10.03.2012].
6. Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA. 1999; 282(13): 1270-80.
7. Bobo JK, Lee NC, Thames SF. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst. 2000; 92(12): 971-6.
8. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst. 2000; 92(18): 1490-9.
9. Chiarelli AM, Majpruz V, Brown P, Theriault M, Shumak R, Mai V. The contribution of clinical breast examination to the accuracy of breast screening. J Natl Cancer Inst. 2009; 101(18): 1236-43.
10. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151(10): 727-37.
11. Fenton JJ, Rolnick SJ, Harris EL, Barton MB, Barlow WE, Reisch LM, et al. Specificity of clinical breast examination in community practice. J Gen Intern Med. 2007; 22(3): 332-7.
12. Okonkwo QL, Draisma G, der Kinderen A, Brown ML, de Koning HJ. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst. 2008; 100(18): 1290-300.
13. Kösters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev. 2003;(2): CD003373.
14. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002; 94(19): 1445-57.
15. Hackshaw AK, Paul EA. Breast self-examination and death from breast cancer: a meta-analysis. Br J Cancer. 2003; 88(7): 1047-53. 16. Corsetti V, Houssami N, Ferrari A, Ghirardi M, Bellarosa S, Angelini O, et al. Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost. Eur J Cancer. 2008; 44(4): 539-44.
17. Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, et al. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer. 2006; 106(4): 732-42.
18. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst. 1993; 85(20): 1644-56.
19. Elwood M, Cox B, Richardson A. The effectiveness of breast cancer screening by mammography in younger women: correction. Online J Curr Clin Trials. 1994; Doc No 121: [385 words; 4 paragraphs].
20. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002; 359(9310): 909-19.
21. Freedman DA, Petitti DB, Robins JM. On the efficacy of screening for breast cancer. Int J Epidemiol. 2004; 33(1): 43-55.
22. Breast cancer screening. Eds.:Vainio H, Bianchini F.: IARC Handbook of cancer prevention. Lyon: IARC Pres; 2002. p. 7.
23. National Cancer Institute. Breast Cancer Screening_(PDQ®):_http://cancer.gov/cancertopics/pdq/screening/breast/healthprofessional [Erişim Tarihi: 15.12.2011].
24. Schopper D, de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009; 45(11): 1916-23.
25. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, et al. NCCN clinical practice guidelines in oncology breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009; 7(10): 1060-96.
26. Lee CH, Dershaw DD, Kopans D,Evans P, Monsees B, Monticciolo D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010; 7(1): 18-27.
27. American College of Obstetricians-Gynecologists. Practice bulletin no. 122: Breast cancer screening. Obstet Gynecol. 2011; 118(2): 372-82.
28. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009; 59(1): 27-41.
29. Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention. Eur J Cancer. 2000; 36(12): 1473-8.
30. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151(10): 716-26.
31. Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK, et al. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007; 146(7): 511-5.
32. U.S. Preventive Services Task Force. Screening for_Breast_Cancer._ [Erişim Tarihi: 15.02.2012].
33. Statistical analyses of National Breast Cancer Registry Program of Turkish Federation of Breast Societies 2008 Executive summary of the national cancer control programmes: policies and managerial guidelines. Geneva: World Health Organization; 2002.
34. Özmen V. Meme Kanseri Tarama Yöntemleri. Meme Sağlığı Dergisi. 2007;3(2): 109-111.
35. Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM. Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst. 2008; 100(15): 1082-91.
36. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011; 155(8): 481-92.
37. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009; 151(10): 738-47.
38. Screening for Breast Cancer, Geneva: World Health Organization, 2009. Available at: http://www.who.int/cancer/detection/breastcancer/en/index.html [Erişim Tarihi: 15.12.2011].
39. Sirovich BE and Sox HC Jr. Breast cancer screening. Surg Clin N Am. 1999; 79(5): 961-990.
40. Feig SA, D'Orsi CJ, Hendrick RE, Jackson VP, Kopans DB, Monsees B, et al. American College of Radiology guidelines for breast cancer screening. AJR Am J Roentgenol. 1998; 171(1): 29-33.
41. American College of Obstetricians-Gynecologists. Practice bulletin no. 122: Breast cancer screening. Obstet Gynecol. 2011; 118(2): 372-82.
42. Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J. Is screening mammography effective in elderly women? Am J Med. 2000; 108(2): 112-9.
43. Van Dijck JA, Holland R, Verbeek AL, Hendricks JH, Mravunac M. Efficacy of mammographic screening of the elderly: a case-referent study in the Nijmegen program in The Netherlands. J Natl Cancer Inst. 1994; 86(12): 934-8.
44. Schonberg MA, Silliman RA, Marcantonio ER. Weighing the benefits and burdens of mammography screening among women age 80 years or older. J Clin Oncol. 2009; 27(11): 1774-80.
45. Cody HS III: Current surgical management of breast cancer. Current Opin Obstet Gynecol. 2002; 14(1): 45-52.
46. Moore SG, Shenoy PJ, Fanucchi L, Tumeh JW, Flowers CR. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res. 2009; 9: 9.
47. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004; 292(11): 1317-25.
48. Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P, Hendriks JH, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001; 93(14): 1095-1102.
49. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005; 23(33): 8469-76.
50. Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology. 2007; 244(2): 381-8.
51. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 365(9473): 1769-78.
52. Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005; 103(9): 1898-1905.
53. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57(2): 75-89.

APA	KILBAŞ Z, YILDIZ R, ÖZTÜRK E (2012). Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. , 225 - 230.
Chicago	KILBAŞ Zafer,YILDIZ Ramazan,ÖZTÜRK ERKAN Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. (2012): 225 - 230.
MLA	KILBAŞ Zafer,YILDIZ Ramazan,ÖZTÜRK ERKAN Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. , 2012, ss.225 - 230.
AMA	KILBAŞ Z,YILDIZ R,ÖZTÜRK E Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. . 2012; 225 - 230.
Vancouver	KILBAŞ Z,YILDIZ R,ÖZTÜRK E Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. . 2012; 225 - 230.
IEEE	KILBAŞ Z,YILDIZ R,ÖZTÜRK E "Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?." , ss.225 - 230, 2012.
ISNAD	KILBAŞ, Zafer vd. "Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?". (2012), 225-230.

APA	KILBAŞ Z, YILDIZ R, ÖZTÜRK E (2012). Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. TSK Koruyucu Hekimlik Bülteni, 11(2), 225 - 230.
Chicago	KILBAŞ Zafer,YILDIZ Ramazan,ÖZTÜRK ERKAN Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. TSK Koruyucu Hekimlik Bülteni 11, no.2 (2012): 225 - 230.
MLA	KILBAŞ Zafer,YILDIZ Ramazan,ÖZTÜRK ERKAN Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. TSK Koruyucu Hekimlik Bülteni, vol.11, no.2, 2012, ss.225 - 230.
AMA	KILBAŞ Z,YILDIZ R,ÖZTÜRK E Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. TSK Koruyucu Hekimlik Bülteni. 2012; 11(2): 225 - 230.
Vancouver	KILBAŞ Z,YILDIZ R,ÖZTÜRK E Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?. TSK Koruyucu Hekimlik Bülteni. 2012; 11(2): 225 - 230.
IEEE	KILBAŞ Z,YILDIZ R,ÖZTÜRK E "Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?." TSK Koruyucu Hekimlik Bülteni, 11, ss.225 - 230, 2012.
ISNAD	KILBAŞ, Zafer vd. "Meme kanseri için erken tanı ve tarama programları nasıl olmalıdır?". TSK Koruyucu Hekimlik Bülteni 11/2 (2012), 225-230.